VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

CAR-T Meeting 2021 | NK-CAR immunotherapy: where are we now?

Natural killer (NK) cells are an essential component of the innate immune system and can provide a valuable source of allogeneic adoptive therapy. Concetta Quintarelli, PhD, Bambino Gesù Children Hospital, IRCCS, Rome, Italy, discusses the generation of allogeneic CAR products, in particular CAR NK-cells. Prof. Quintarelli reveals that using bioreactors, her group has generated up to 300 doses of CAR NK-cells. Although the transition from autologous to allogeneic products is challenging, especially the manufacturing process, the group is now generating the NK-cell banks for both hematological malignancies and solid tumors. This interview took place during the 3rd European CAR T-cell Meeting.